EUDIAL actively contributed in the creation of the special web page pertaining to global outbreak of COVID-19
How to set the stage for a full-fledged clinical trial testing “incremental haemodialysis” project, submitted by EUDIAL, was selected to be one of the projects to be supported by the ERA-EDTA through the Long Term Fellowship Programme.
The Council of the European Renal Association-European Dialysis Transplant Association (ERA-EDTA) has officially approved the creation of a Working Group aimed at encouraging research, communicating knowledge, teaching and contributing to education in the field of haemodialysis. The acronym EUDIAL, standing for European Dialysis Working Group, has been chosen to best summarize its activity and mission. The vision and mission of this Working Group as formulated by the ERA-EDTA are clearly identified to improve outcomes of chronic kidney disease patients by enhancing the quality of dialysis therapies in their broader sense and facilitating collaborative research in this field.
Given the increasing scientific interest in convective therapies (hemodiafiltration and hemofiltration), the working group has decided to focusing on convective renal replacement therapies as the first aim. The rationale of this first mission is supported by several facts that include an increasing interest in convective therapies translating in a rapid growth of patients treated by modern versions of these therapies and several reports suggesting an improvement in CKD patient outcomes.
In addition, the European nephrology community has been leading in this field of renal replacement therapy for more than two decades. The concept of ultrapure dialysis fluid introduced in 1987 is now accepted as a standard for all dialysis forms. The European notified bodies have certified water treatment systems and hemodialysis machines for online production of substitution fluid. The European scientific community has launched the first randomized controlled trials comparing outcomes of CKD patients treated either by hemodiafiltration/hemofiltration or conventional hemodialysis. The highest prevalence of CKD patients treated by hemodiafiltration is found in Europe and it is increasing regularly over the time.
Carlo Basile (Italy) – Chair
Sandip Mitra (United Kingdom) – Vice Chair
Christian Combe (France)
Adrian Covic (Romania)
Mehmet Kanbay (Turkey)
Frank van der Sande (Netherlands)
CALL FOR BOARD CANDIDATES
In 2020 the Board composition of EUDIAL Working Group must be partially renewed and 4 new members will be elected.
Before applying, please read the Working Groups regulations carefully and consider that to be eligible for the Board a member must have been an ordinary member of the WG for at least 2 years (or from its creation) or have a proven track record of relevant scientific expertise that would justify his/her being part of the Board; ERA-EDTA Full members (exceptions to this last rule can only be made for non-nephrologists). In particular women and young members are encouraged to actively send an application.
Each candidate must send his/her application and CV (the use of this specific template is mandatory) together with two supporting letters from two Working Group members (Board or Ordinary members) to email@example.com, the Working Group secretariat will, indeed, collect the candidatures on behalf of the Working Group Vice Chairs.
The deadline to apply is July 31, 2020. No candidatures sent after this date will be accepted; furthermore, candidatures not fulfilling all the above mentioned requirements will not be taken into consideration.
HOW TO JOIN THE WORKING GROUP
Being a ordinary member of the EUDIAL means being part of a network which facilitates exchanges of ideas on basic science research and new treatment protocols.
Becoming an ordinary member of the EUDIAL is FREE OF CHARGE (ERA-EDTA Membership is not mandatory) and is also open to non-nephrologists.
By joining the EUDIAL you will receive constant updates on the Working Group initiatives be included in the Directory of EUDIAL’ ordinary members and start networking with colleagues from all over the world.
Randomized controlled trial (RCT) on incremental haemodialysis – EUDIAL is ready to start a very ambitious project: an RCT in incident HD patients is being designed: its name is “REAL LIFE” which stands for “RandomizEd clinicAL triaL on the efficacy and saFety of incremental haEmodialysis”. The study aims at being a possible turning point document capable of impacting the patients’ quality of life and reducing the costs of treatment, the project might be of some interest for the EU. How to set the stage for a full-fledged clinical trial testing “incremental haemodialysis”, submitted by EUDIAL, was selected to be one of the projects to be supported by the ERA-EDTA though the Long Term Fellowship Programme. The Association will be granting one young member of the ERA-EDTA the possibility to be involved in the project by providing him/her a one year Long Term Fellowship.
The CONVINCE study, a European prospective randomised controlled trial comparing high-volume on-line haemodiafiltration and high-flux haemodialysis, sponsored by European Union’s Horizon 2020 research and innovation programme (grant agreement No 754803), has now recruited more than 500 patients from dialysis centres spread across Europe from Portugal to Romania. This trial is designed to compare all-cause mortality, cause specific mortality, hospitalisations, quality of life and health care costs between modalities (www.convincetrial.eu).
EUDIAL Pooling project of trials in HDF (ongoing) a meta-analysis of the individual patient data from the 4 prospective trials of haemodiafiltration compared to haemodialysis.
SPEEDY is a user-friendly tool for incremental haemodialysis prescription created by Prof. F. Casino and Dr C. Basile (EUDIAL Chair). It is freely available here. Read the related article on Nephrology Dialysis Transplantation here.